Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SANJAY YATHIRAJ

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1508851718
CMS profile
23074
Location
BRADENTON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$9,523.87

197 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 197 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SANJAY YATHIRAJ

NPI 1508851718 · CMS profile ID 23074

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

BRADENTON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 197 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508851718?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SANJAY YATHIRAJ, NPI 1508851718, CMS profile ID 23074. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 197 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508851718?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). SANJAY YATHIRAJ, NPI 1508851718, CMS profile ID 23074. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 197 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508851718?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
SANJAY YATHIRAJ, NPI 1508851718, CMS profile ID 23074, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 197 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1508851718?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

197 matching records · $9,523.87 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 197 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 197.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
UCB, Inc. $10.1405/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143127652 CMS
PFIZER INC. $8.4405/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131430456 CMS
ABBVIE INC. $15.1305/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106373168 CMS
ABBVIE INC. $2,625.0005/29/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106373170 CMS
Neurocrine Biosciences, Inc. $5.4305/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150887753 CMS
Eisai Inc. $19.2205/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110779783 CMS
Alnylam Pharmaceuticals Inc. $21.9505/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125826837 CMS
PFIZER INC. $22.7705/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131479116 CMS
Lilly USA, LLC $18.2205/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135413357 CMS
Teva Pharmaceuticals USA, Inc. $6.2305/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151454159 CMS
ARGENX US, INC. $22.9405/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142102240 CMS
Teva Pharmaceuticals USA, Inc. $7.3305/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151454155 CMS
Teva Pharmaceuticals USA, Inc. $25.7005/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151454157 CMS
PFIZER INC. $4.7705/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131438265 CMS
ABBVIE INC. $15.1705/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106373166 CMS
Biogen, Inc. $20.7205/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104823200 CMS
Neurocrine Biosciences, Inc. $7.8405/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150884501 CMS
Takeda Pharmaceuticals U.S.A., Inc. $29.2505/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137700782 CMS
UCB, Inc. $20.5305/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143127643 CMS
ABBVIE INC. $121.9805/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106373162 CMS
ABBVIE INC. $12.0605/02/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106373164 CMS
UCB, Inc. $25.6104/30/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155570791 CMS
Neurocrine Biosciences, Inc. $38.7704/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150815802 CMS
PFIZER INC. $3.5904/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131421261 CMS
HARMONY BIOSCIENCES LLC $32.5104/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126061480 CMS
LivaNova USA, Inc. $14.6004/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152791163 CMS
LivaNova USA, Inc. $13.8404/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152791165 CMS
ABBVIE INC. $15.2404/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106373160 CMS
Neurocrine Biosciences, Inc. $124.6404/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150809301 CMS
Teva Pharmaceuticals USA, Inc. $9.8404/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151454141 CMS
JAZZ PHARMACEUTICALS INC. $15.0404/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150218583 CMS
Abbott Laboratories $143.7904/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125101732 CMS
Inspire Medical Systems, Inc. $18.8404/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148129085 CMS
Teva Pharmaceuticals USA, Inc. $31.0804/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151454139 CMS
Takeda Pharmaceuticals U.S.A., Inc. $25.0904/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137700780 CMS
Novartis Pharmaceuticals Corporation $18.5804/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087346156 CMS
Novartis Pharmaceuticals Corporation $2.3104/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087346158 CMS
Novartis Pharmaceuticals Corporation $78.1004/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087346160 CMS
PFIZER INC. $4.5904/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131421257 CMS
E.R. Squibb & Sons, L.L.C. $33.9603/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101760623 CMS
ABBVIE INC. $19.9303/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106373158 CMS
Neurocrine Biosciences, Inc. $5.6203/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150887547 CMS
Otsuka America Pharmaceutical, Inc. $22.0503/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119007533 CMS
EMD Serono, Inc. $19.7903/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120238736 CMS
GE HEALTHCARE $24.8103/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144682860 CMS
ABBVIE INC. $18.5003/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106373156 CMS
PFIZER INC. $5.2203/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131420961 CMS
PFIZER INC. $23.9903/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131235495 CMS
GE HEALTHCARE $19.5203/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144681507 CMS
ABBVIE INC. $17.2603/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106373154 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $22,165.57 164
PY2020 $20,638.75 144
PY2021 $33,181.45 221
PY2022 $29,971.17 177
PY2023 $17,990.00 206
PY2024 $9,523.87 197
PY2025 $12,376.28 186

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $497,201.07 37
PY2024 Principal investigator $827,705.44 17
PY2023 Recipient $150.00 1
PY2023 Principal investigator $628,399.76 29
PY2022 Principal investigator $170,009.58 7
PY2021 Recipient $1,130.00 1
PY2021 Principal investigator $48,658.99 426
PY2020 Recipient $5,000.00 2
PY2020 Principal investigator $22,844.76 4
PY2019 Recipient $7,000.00 2
PY2019 Principal investigator $29,433.65 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

37 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Pacira Pharmaceuticals Incorporated $1,962.84 12/09/2025 Non-covered Recipient Entity
Nova Clinical Research, LLC
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304367
Principal investigator 1 Pacira Pharmaceuticals Incorporated $524.00 11/12/2025 Non-covered Recipient Entity
Nova Clinical Research, LLC
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304398
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,134.00 11/12/2025 Non-covered Recipient Entity
NOVA CLINICAL RESEARCH LLC
A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care No dispute reported 06/30/2026 1223288195
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,134.00 11/12/2025 Non-covered Recipient Entity
NOVA CLINICAL RESEARCH LLC
A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care No dispute reported 06/30/2026 1223288197
Principal investigator 1 Pacira Pharmaceuticals Incorporated $13.16 11/04/2025 Non-covered Recipient Entity
Nova Clinical Research, LLC
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304387
Principal investigator 1 Pacira Pharmaceuticals Incorporated $21.65 10/30/2025 Non-covered Recipient Entity
Nova Clinical Research, LLC
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304383
Principal investigator 1 Novartis Pharmaceuticals Corporation $241.15 10/28/2025 Non-covered Recipient Entity
NOVA CLINICAL RESEARCH
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190308370
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 10/13/2025 Non-covered Recipient Entity
NOVA CLINICAL RESEARCH LLC
A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care No dispute reported 06/30/2026 1223286735
Principal investigator 1 Pacira Pharmaceuticals Incorporated $1,962.84 09/26/2025 Non-covered Recipient Entity
Nova Clinical Research, LLC
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304379
Principal investigator 1 Pacira Pharmaceuticals Incorporated $262.00 09/02/2025 Non-covered Recipient Entity
Nova Clinical Research, LLC
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304391
Principal investigator 1 Pacira Pharmaceuticals Incorporated $981.42 08/26/2025 Non-covered Recipient Entity
Nova Clinical Research, LLC
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304395
Principal investigator 1 Merz Pharmaceuticals, LLC $48,462.00 08/11/2025 Non-covered Recipient Entity
Nova Clinical Research
Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment No dispute reported 06/30/2026 1232647458
Principal investigator 1 Merz Pharmaceuticals, LLC $152,759.00 08/11/2025 Non-covered Recipient Entity
Nova Clinical Research
Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment No dispute reported 06/30/2026 1232647460
Principal investigator 1 Pacira Pharmaceuticals Incorporated $981.42 08/06/2025 Non-covered Recipient Entity
Nova Clinical Research, LLC
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304372
Principal investigator 1 GENZYME CORPORATION $33,300.00 08/04/2025 Non-covered Recipient Entity
Nova Clinical Research Bradenton
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226105177
Principal investigator 1 Alexion Pharmaceuticals, Inc. $5,715.00 07/25/2025 Non-covered Recipient Entity
NOVA CLINICAL RESEARCH
A Phase 3, Randomized, Double blind, Placebo controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1185544519
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,065.39 07/14/2025 Non-covered Recipient Entity
Roskamp Institute
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 1) No dispute reported 06/30/2026 1235994145
Principal investigator 1 Merz Pharmaceuticals, LLC $32,525.00 05/20/2025 Non-covered Recipient Entity
Nova Clinical Research
Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment No dispute reported 06/30/2026 1232647454
Principal investigator 1 Pacira Pharmaceuticals Incorporated $981.42 05/07/2025 Non-covered Recipient Entity
Nova Clinical Research, LLC
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304330
Principal investigator 1 Eli Lilly and Company $2,943.00 05/06/2025 Non-covered Recipient Entity
ROSKAMP INSTITUTE INC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187887814
Principal investigator 1 Merz Pharmaceuticals, LLC $59,784.00 04/10/2025 Non-covered Recipient Entity
Nova Clinical Research
Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment No dispute reported 06/30/2026 1232647456
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,154.80 03/20/2025 Non-covered Recipient Entity
THE ROSKAMP INSTITUTE INC
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190313457
Principal investigator 1 Sage Therapeutics, LLC $4,428.02 03/06/2025 Non-covered Recipient Entity
BRADENTON RESEARCH CENTER INC
Study to Evaluate SAGE-324 in Participants With Essential Tremors No dispute reported 06/30/2026 1206580205
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,750.00 02/27/2025 Non-covered Recipient Entity
NOVA CLINICAL RESEARCH LLC
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190304857
Principal investigator 1 Pacira Pharmaceuticals Incorporated $2,926.02 02/11/2025 Non-covered Recipient Entity
Nova Clinical Research, LLC
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304335
Principal investigator 1 Pacira Pharmaceuticals Incorporated $34.42 02/11/2025 Non-covered Recipient Entity
Nova Clinical Research, LLC
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304347
Principal investigator 1 Pacira Pharmaceuticals Incorporated $43.30 02/11/2025 Non-covered Recipient Entity
Nova Clinical Research, LLC
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304352
Principal investigator 1 Pacira Pharmaceuticals Incorporated $13.40 02/11/2025 Non-covered Recipient Entity
Nova Clinical Research, LLC
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304356
Principal investigator 1 Pacira Pharmaceuticals Incorporated $5,816.46 02/11/2025 Non-covered Recipient Entity
Nova Clinical Research, LLC
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304360
Principal investigator 1 Pacira Pharmaceuticals Incorporated $32.90 02/11/2025 Non-covered Recipient Entity
Nova Clinical Research, LLC
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304364
Principal investigator 1 Pacira Pharmaceuticals Incorporated $524.00 02/07/2025 Non-covered Recipient Entity
Nova Clinical Research, LLC
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304326
Principal investigator 1 Pacira Pharmaceuticals Incorporated $4,907.10 02/07/2025 Non-covered Recipient Entity
Nova Clinical Research, LLC
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304340
Principal investigator 1 Pacira Pharmaceuticals Incorporated $1,962.84 02/07/2025 Non-covered Recipient Entity
Nova Clinical Research, LLC
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304344
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,356.95 01/09/2025 Non-covered Recipient Entity
NOVA CLINICAL RESEARCH
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190308372
Principal investigator 1 Eli Lilly and Company $213.25 01/07/2025 Non-covered Recipient Entity
ROSKAMP INSTITUTE INC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187887460
Principal investigator 1 Merz Pharmaceuticals, LLC $74,102.00 01/06/2025 Non-covered Recipient Entity
Nova Clinical Research
Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment No dispute reported 06/30/2026 1232647452
Principal investigator 1 Novartis Pharmaceuticals Corporation $35,182.32 01/01/2025 Non-covered Recipient Entity
ROSKAMP INSTITUTE
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190305661